Dynamics of Elongation Factor 2 Kinase Regulation in Cortical Neurons in Response to Synaptic Activity

Citation for published version:

Digital Object Identifier (DOI):
10.1523/JNEUROSCI.2866-14.2015

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Journal of Neuroscience

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Dynamics of Elongation Factor 2 Kinase Regulation in Cortical Neurons in Response to Synaptic Activity

Justin W. Kenney, Oksana Sorokina, Maja Genheden, Anatoly Sorokin, J. Douglas Armstrong, and Christopher G. Proud

1University of Southampton, Centre for Biological Sciences, Southampton, SO17 1BJ, United Kingdom, 2University of Edinburgh, School of Informatics, Edinburgh, EH8 9AB, United Kingdom, and 3Institute of Cell Biophysics, Pushchino, 142290, Russia

The rapid regulation of cell signaling in response to calcium in neurons is essential for real-time processing of large amounts of information in the brain. A vital regulatory component, and one of the most energy-intensive biochemical processes in cells, is the elongation phase of mRNA translation, which is controlled by the Ca$^{2+}$/CaM-dependent elongation factor 2 kinase (eEF2K). However, little is known about the dynamics of eEF2K regulation in neurons despite its established role in learning and synaptic plasticity. To explore eEF2K dynamics in depth, we stimulated synaptic activity in mouse primary cortical neurons. We find that synaptic activity results in a rapid, but transient, increase in eEF2K activity that is regulated by a combination of AMPA and NMDA-type glutamate receptors and the mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) pathways. We then used computational modeling to test the hypothesis that considering Ca$^{2+}$-coordinated MEK/ERK, mTORC1, and eEF2K activation is sufficient to describe the observed eEF2K dynamics. Although such a model could partially fit the empirical findings, it also suggested that a crucial positive regulator of eEF2K was also necessary. Through additional modeling and empirical evidence, we demonstrate that AMP kinase (AMPK) is also an important regulator of synaptic activity-driven eEF2K dynamics in neurons. Our combined modeling and experimental findings provide the first evidence that it is necessary to consider the combined interactions of Ca$^{2+}$ with MEK/ERK, mTORC1, and AMPK to adequately explain eEF2K regulation in neurons.

Key words: AMPK; bicuculline; dynamical systems; ERK; mTORC1; translation elongation

Introduction
The fast and dynamic regulation of cell signaling cascades by Ca$^{2+}$ in neurons is integral for a variety of neurophysiological processes (Badings, 2013), such as the modulation of the machinery involved in protein synthesis (Costa-Mattioli et al., 2009). Protein synthesis involves three phases, initiation, elongation, and termination, with the elongation phase being regulated by the Ca$^{2+}$/calmodulin (CaM)-dependent elongation factor 2 kinase (eEF2K; Kenney et al., 2014), thus making it the step most directly regulated by Ca$^{2+}$. eEF2K phosphorylates eEF2 at T56, which impairs its ability catalyze ribosomal translocation, thereby slowing overall rates of elongation (Nairn and Palfrey, 1987; Price et al., 1991). Moreover, eEF2K has been implicated recently in a variety of neuronal functions, such as synaptic plasticity, learning and memory, cytoprotection, and ischemia (Park et al., 2008; Im et al., 2009; Gildish et al., 2012; Romero-Ruiz et al., 2012; Leprivier et al., 2013). Although previous work has found that stimuli that increase Ca$^{2+}$ influx in neurons, such as elevated synaptic activity, can result in an increase in eEF2 phosphorylation (Lenz and Avruch, 2005; Verpelli et al., 2010; Heise et al., 2014), the complex dynamics of eEF2K regulation have not been explored.

In addition to positive regulation by Ca$^{2+}$/CaM, a number of signaling pathways have been found to negatively regulate eEF2K activity, such as the mammalian target of rapamycin complex 1 (mTORC1) and mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) pathways (Kenney et al., 2014). In neuronal preparations, the mTORC1 pathway has been studied extensively as a negative regulator of eEF2K in neurons (Carroll et al., 2004; Inamura et al., 2005; Weatherill et al., 2011), whereas the MEK/ERK pathway has received comparatively little attention (Belelovskaya et al., 2005; Kanhema et al., 2006) but has been studied more thoroughly in non-neuronal preparations (Wang et al., 2001; Wang and Proud, 2002). Importantly, synaptic activity-induced stimulation of mTORC1 and MEK/ERK in neurons requires Ca$^{2+}$ influx (Lenz and Avruch, 2005; Wang et
were isolated as described previously (Cruz Biotechnology (catalog #sc-74459). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; catalog #G8795) and p-AMPK T172 (catalog #2535), and AMPK (catalog #2332), p-ERK T202/Y204 (catalog #4370), p-ribosomal protein from Sigma. MycoZap was from Lonza. Rapamycin was from Millipore, from Selleck Chemicals, and A769662 [6,7-dihydro-4-hydroxy-3-(2-biphenyl)-6-oxo-thieno[2,3-d]quinoxaline (NBQX), α- methyl-(4-carboxyphenyl)glycine (MCPG), and bicuculline were from Sigma. MycoZap was from Lonza. Rapamycin was from Millipore, AZD6244 [6-(4-bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d][imidazol-5-carboxamide] was from Selleck Chemicals, and A769662 [6,7-dihydro-4-hydroxy-3-(2’-hydroxy-1,1’-biphenyl)-4-yl]-6-oxo-thiophen[2,3-b]pyridine-5-carbonitrile was from Tocris Bioscience. The anti-phosphorylated (p) eEF2 (T56) antibody was custom made by Eurogentec. Antibodies for eEF2 (catalog #2332), p-ERK T202/Y204 (catalog #4370), p-ribosomal protein S6 (p-S6) S240/244 (catalog #2215), p-acetyl-CoA carboxylase (ACC; catalog #3661), AMPK T172 (catalog #2535), and AMPK (catalog #2532) were purchased from Cell Signaling Technologies; antibodies for glyceroylaldehyde 3-phosphate dehydrogenase (GAPDH; catalog #G8795) and tubulin (catalog #T6199) were from Sigma. The antibody for total S6 was from either Cell Signaling Technologies (catalog #2317) or Santa Cruz Biotechnology (catalog #sc-74459).

Primary neuronal cell culture. Primary cultures of cortical neurons were isolated as described previously (Wong et al., 2005). Cortices were isolated in ice-cold HBSS from P0 or P1 C57BL/6 mice of either sex. All procedures involving mice were done in accordance with United Kingdom Animals (Scientific Procedures) Act 1986. Tissue was gently minced isolated in ice-cold HBSS from P0 or P1 C57BL/6J mice of either sex. All procedures involving mice were done in accordance with United Kingdom Animals (Scientific Procedures) Act 1986. Tissue was gently minced moved and replaced with Neurobasal medium containing 2% B27 supplement, 2,3-dihydroxy-6-nitro-7-sulfonyl-benzo/fquinoxaline (NBQX), α- methyl-(4-carboxyphenyl)glycine (MCPG), and bicuculline were from Sigma. MycoZap was from Lonza. Rapamycin was from Millipore, AZD6244 [6-(4-bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d][imidazol-5-carboxamide] was from Selleck Chemicals, and A769662 [6,7-dihydro-4-hydroxy-3-(2’-hydroxy-1,1’-biphenyl)-4-yl]-6-oxo-thiophen[2,3-b]pyridine-5-carbonitrile was from Tocris Bioscience. The anti-phosphorylated (p) eEF2 (T56) antibody was custom made by Eurogentec. Antibodies for eEF2 (catalog #2332), p-ERK T202/Y204 (catalog #4370), p-ribosomal protein S6 (p-S6) S240/244 (catalog #2215), p-acetyl-CoA carboxylase (ACC; catalog #3661), AMPK T172 (catalog #2535), and AMPK (catalog #2532) were purchased from Cell Signaling Technologies; antibodies for glyceroylaldehyde 3-phosphate dehydrogenase (GAPDH; catalog #G8795) and tubulin (catalog #T6199) were from Sigma. The antibody for total S6 was from either Cell Signaling Technologies (catalog #2317) or Santa Cruz Biotechnology (catalog #sc-74459).

Primary neuronal cell culture. Primary cultures of cortical neurons were isolated as described previously (Wong et al., 2005). Cortices were isolated in ice-cold HBSS from P0 or P1 C57BL/6 mice of either sex. All procedures involving mice were done in accordance with United Kingdom Animals (Scientific Procedures) Act 1986. Tissue was gently minced and digested in Neurobasal medium containing papain (20 U/mL) and 0.32 mg/mL l-cysteine at 37°C for 20 min, followed by 31°C for an additional 20 min. Tissue was then washed once in Neurobasal medium containing 1 mg/mL each of BSA and STI and then incubated at 37°C for 2 min in Neurobasal medium containing 10 mg/mL each of BSA and STI. The dissociated tissue was then washed once in Neurobasal medium and triturated with fire-polished glass pipettes. Cells were then washed in Neurobasal medium and passed through a 40 μm cell strainer, after which they were plated onto poly-Ł-lysine-coated culture dishes at high density (1500–2000 cells/mm²). After 1 h, overlying medium was removed and replaced with Neurobasal medium containing 2% B27 supplement, 0.5 mM l-glutamine, and either 100 U/mL penicillin/streptomycin or 1X MycoZap. One-half of the medium was replaced with fresh medium every 3–4 d. Cells were used in experiments at 10–12 DIV.

Drugs were added to neuronal cultures by diluting into 500 μL of overlying medium before addition to the culture plate to ensure rapid and even diffusion. APV (100 μM), nifedipine (5 μM), MCPG (100 μM), and NBQX (10 μM) were added 20–30 min before bicuculline (50 μM) stimulation unless otherwise noted. AZD6244 (10 μM) was added 10 min and rapamycin (100 ns) and A769662 (100 μM) 60 min before the indicated treatments. EGTA (5 mM) was applied for 10 min.

SDS-PAGE. The overlying medium was removed, and cells were lysed via addition of 95°C 1X Laemmli’s sample buffer. Cell lysates were vortexed vigorously for 10 s and centrifuged for 15 min at 20,000 × g. After boiling for 5 min, equal amounts of each sample were resolved on 12.5% polyacrylamide gels and transferred to a nitrocellulose membrane (0.45 μm pore size) via electrobloct. Membranes were blocked in 5% nonfat dry milk or 2% BSA in either PBS containing 0.1% Tween (PBST) or Tris-buffered saline containing 0.1% Tween (TBSST) at room temperature for 45 min, washed, and then incubated with primary antibody in PBST or TBSST containing 2% BSA for 1 h at room temperature or overnight at 4°C. After washing, membranes were incubated with appropriate secondary antibodies in PBST and 2% BSA and imaged using the LI-COR Odyssey infrared imaging system.

Statistical analyses. Immunoblot data were quantified using LI-COR Odyssey software (version 3.0), and experimental treatments were expressed relative to cells that received no treatment. Data were analyzed using one-way ANOVAs or two-way ANOVAs as appropriate and followed up by Dunnett’s post hoc t tests with untreated neurons as the comparison group. If only two groups were compared, independent samples t tests were performed. SPSS version 20.0.0 (IBM) was used for all statistical analyses.

Modeling. The model was developed in Systems Biology Toolbox 2 (SBTBTOOLBOX2; version Rev1176, R2012a) for MATLAB (version 7.11.1, R2010) and fitted with simplex and simulated annealing optimization algorithms from the SBPD package in SBTBTOOLBOX2 (Schmidt and Jirstrand, 2006; Banks et al., 2008). Throughout the model, Michaelis–Menten kinetics was used to describe the enzymatic reactions of phosphorylation and dephosphorylation, and the law of mass action was used to describe protein binding and unbinding. A more detailed account of the modeling is available as supplemental material.

The model included three conceptual building blocks: (1) an ERK module, (2) an mTORC1 module, and (3) an eEF2K module. Interactions in the model were built based on known interactions of the different module components with the MEK/ERK and mTORC1 modules providing combined inhibitory action on eEF2K with no feedback. We started by fitting parameters for the frame model (MEK/ERK and mTORC1 modules only) in response to the application of bicusculine. During the procedure, parameters were allowed to change within biologically plausible ranges provided by literature when available. The frame model was fitted simultaneously to time series curves for p-ERK and p-S6 kinase 1 (S6K1; p-S6 240/244 data were used as an indicator of S6K1 activity). Coordinated model, calcium in limited substrate specificity and is not known to dephosphorylate any of the components considered in the model (Li et al., 2011). We also included a competitive mechanism for
inhibition of MEK by AZD6244 (Huynh et al., 2007). Finally, in the most recent version of the model, the cascade was updated based on the study by Caloca et al. (2003) in which we substituted receptor “R” in the Hornberg model to Ras activation by RasGRP in response to elevated Ca\textsuperscript{2+}.

**mTORC1 submodel.** We did not attempt to describe the overall complexity of the mTORC1 pathway in the model, because there are numerous crosstalk pathways. An overly detailed description would invariably result in the inclusion of a large number of parameters for which we lack exact information and reduce biological plausibility of the model. Given the specific hypothesis under consideration and the experimental data available, we identified key elements in the mechanism that allowed for an accurate reproduction of experimental data with minimal details. Thus, mTORC1 was modeled as being activated by elevated Ca\textsuperscript{2+}/CaM based on previous findings (Lenz and Avruch, 2005; Gulati et al., 2008), followed by activation of the complex by phosphorylation. We also included the activation of mTORC1 by the MEK/ERK pathway and mTORC1-stimulated activation of S6K1 and suppression of PP2A (Hui et al., 2005). Inhibition of mTORC1 by rapamycin was modeled as binding to mTORC1 and preventing its kinase function (Ballou and Lin, 2008).

**eEF2K submodel.** eEF2K was modeled as being activated by fully occupied Ca\textsuperscript{2+}/CaM and dephosphorylation of eEF2 and eEF2K as regulated by PP2A (Redpath et al., 1993). For the inhibition of eEF2K by p-S6K1 and p-ERK, we considered two possible mechanisms: (1) p-ERK and p-S6K1 phosphorylate the eEF2K/Ca\textsuperscript{2+}/CaM-bound complex, which then turns eEF2K to an inactive state; or (2) phosphorylation of eEF2K by p-ERK and p-S6K1 prevent binding of eEF2K to Ca\textsuperscript{2+}/CaM. The second mechanism was used to reproduce experimental curves, even when the frame parameters were allowed to change in a wide, biologically plausible range (data not shown). Thus, we made use of the first mechanism described above in building the eEF2K module.

**Ca\textsuperscript{2+}/CaM interaction.** The temporal profile and shape of the bicuculline-induced changes in Ca\textsuperscript{2+} influx were modeled as an event when intracellular Ca\textsuperscript{2+} is elevated based on experimental evidence (Bengston et al., 2013). Both mTORC1 and eEF2K are modeled as activated by Ca\textsuperscript{2+}/CaM complex binding. Initially, we used a one-step stoichiometric reaction for Ca\textsuperscript{2+}/CaM binding resulting in a shared pool of Ca\textsuperscript{2+}/CaM for activation of both pathways. Although this resulted in an accurate fit of some time series data for the framework model, it was insufficient when including eEF2K and experiments using AZD6244 and rapamycin because the mTORC1 and eEF2K systems competed for the restricted pool of Ca\textsuperscript{2+}/CaM. Considering that the two lobes of CaM have distinct Ca\textsuperscript{2+} affinities (Faas et al., 2011), we used a two-step binding of Ca\textsuperscript{2+} to CaM in which half-bound (i.e., two ions per CaM molecule) and fully bound (i.e., four ions) CaM have different interaction targets. With respect to our model, this means that, at a low concentration, CaM preferentially binds to the two high-affinity binding sites at the C terminus, whereas during continuous bicuculline treatment, the level of intracellular Ca\textsuperscript{2+} remains high for 60 min, which allows the full occupation of all four CaM binding sites, including its low-affinity N-terminal lobes. The modeling suggests that half-bound CaM preferentially binds mTORC1, whereas fully bound CaM preferentially binds eEF2K.

**AMPK pathway.** The AMPK subsystem was added to the initial model to generate a refined model. We used a mechanism in which binding of Ca\textsuperscript{2+}/CaM to Ca\textsuperscript{2+}/CaM-dependent protein kinase kinase-β (CaMKKβ) is followed by AMPK phosphorylation and activation (Hawley et al., 2005; Woods et al., 2005). As in the case of RasGRP, we allowed both stoichiometric forms of Ca\textsuperscript{2+}/CaM to contribute to AMPK phosphorylation and activation with their own constants. The model was built such that p-AMPK activates eEF2K via phosphorylation, leading to increased eEF2 phosphorylation. Activated AMPK is also known to inhibit mTORC1, so an appropriate additional inhibitory term was added to the process describing mTORC1 activation.

**Initial conditions.** One unique aspect of our fitting approach was in our treatment of initial conditions. We assumed that, before treatments, cells were in homeostasis and thus the model has to be in a steady-state condition. In this case, any parameter modifications would change the steady-state concentrations of the system, and initial concentrations were adjusted accordingly. To account for this, we modified the source code of the optimization part of the SBPD package in such a way that, for each parameter set, first the steady state of the original model was calculated, and its stationary concentrations were used as initial conditions for their respective numerical experiments. The modified code is available on request.

**Optimization.** To ensure that the parameter set used in the models here is a global minimum of the optimization process, we used a multi-start method in which we repeated the fitting procedure of the final model 1000 times using initial parameter sets distributed uniformly over the entire biologically plausible range. All of these parameter sets resulted in cost functions at least an order of magnitude worse than our result. However, this multi-start method is known to have several weaknesses (Moles et al., 2003). To further test optimization, the 10 best parameter sets from the multi-start method were chosen as initial points for simulated annealing optimization. Although the result of the simulated annealing tests was considerably better than the multi-start method alone, no parameter set yielded a cost function better than our results, suggesting that our set of final parameters are likely to be the global minimum.

**Sensitivity analysis.** We performed global sensitivity analysis to determine what degree different modeling parameters contributed to model behavior. We used partial rank correlation coefficients (Marino et al., 2008) in the SBPD package with modifications similar to the optimization protocol (i.e., forcing the algorithm to recalculate the steady state for each parameter set; modified code is available on request), ensuring consistency between the fitting and the sensitivity analysis.

**Results**

**Bicuculline-induced eEF2 phosphorylation is rapid and dynamic**

To understand the dynamic regulation of eEF2 phosphorylation by synaptic activity in cortical neurons, primary neuronal cultures were stimulated with bicuculline, a GABA receptor antagonist. Bicuculline was chosen as the stimulus because it is known to increase synaptic activity through disinhibition of endogenous neuronal activity present in cultures, whereas direct GluR stimulation of nonsynaptic receptors triggers cell death pathways (Hardingham et al., 2002; Lee et al., 2005; Hardingham and Bading, 2010). Continuous bicuculline treatment resulted in a rapid but transient increase in eEF2 phosphorylation that decayed to baseline levels after ~20 min of stimulation (Fig. 1A). Given that eEF2 is known to be regulated by the mTORC1 and MEK/ERK pathways (Wang et al., 2001; Carroll et al., 2004; Inamura et al., 2005), we also examined the phosphorylation of ERK1/2 and ribosomal protein S6 at S240/244, readouts of MEK/ERK and mTORC1 pathways, respectively. We chose the phosphorylation of S6 at S240/244 instead of S235/236 as our readout of the mTORC1 pathway given that S240/244 is specifically regulated by mTORC1, whereas S235/236 is also regulated via p90RSK, which is downstream of ERK (Pende et al., 2004). Continuous bicuculline treatment resulted in a rapid and sustained increase in ERK phosphorylation and a slower but sustained increase in S6 phosphorylation in cortical neurons (Fig. 1B, C). The initial round of model development indicated that the first couple of minutes of bicuculline administration were the most important for adequate parameter value determination, so we repeated the first 10 min of the time course but with the inclusion of a 30 s time point. This revealed that eEF2, but not ERK, phosphorylation was elevated after 30 s of bicuculline stimulation (Fig. 1E–H).

**GluR involvement in the bicuculline-induced increase in eEF2 phosphorylation**

To determine the processes required for the increase of eEF2 phosphorylation during both the initial and sustained increase of
induced increase in ERK phosphorylation and found that this increase in eEF2 phosphorylation after 10 min of treatment. We (mGluR) antagonist MCPG prevented the bicuculline-induced increase in eEF2 phosphorylation that was prevented by blocking calcium-permeable NMDARs or calcium-permeable AMPARs (Fig. 2B). These data suggest that, under basal conditions, eEF2K may be very sensitive to small increases in Ca^{2+} levels that can occur independently via NMDARs or calcium-permeable AMPARs (Fig. 2B). However, after 10 min of stimulation, eEF2K activation requires greater Ca^{2+} influx through both NMDARs and AMPARs (Fig. 2A), suggesting that eEF2K is less active in response to relatively small increases in intracellular Ca^{2+}.

To determine whether an influx of extracellular Ca^{2+} is necessary for the bicuculline-induced increase in p-eEF2 and p-ERK, we applied a calcium chelator, EGTA, immediately before the administration of bicuculline for 1 or 10 min. EGTA resulted in a significant reduction in the bicuculline-induced increase in both p-eEF2 and p-ERK (Fig. 2C).

**Involvement of mTORC1 and ERK in the regulation of eEF2K**

Increased synaptic activity results in a rapid initial increase in eEF2 phosphorylation (Fig. 2A). However, after 60 min of bicuculline stimulation, eEF2 phosphorylation remained elevated that is followed by decay back to baseline levels. The decrease in eEF2 phosphorylation back to baseline during prolonged bicuculline stimulation could potentially be attributable to two factors: (1) a decrease in the levels of intracellular calcium resulting in decreased eEF2K activation or (2) an acute inhibition of eEF2K by other cell signaling cascades.

To determine whether there are functionally elevated, physiologically active, calcium levels after a prolonged increase in synaptic activity, we observed that ERK phosphorylation remains elevated after 60 min of bicuculline stimulation and that, at early time points, the bicuculline-induced increase in ERK phosphorylation is prevented by blocking calcium-permeable NMDARs and L-VGCCs (Fig. 2). This suggests that elevated levels of calcium influx may maintain the increase in ERK phosphorylation after 60 min of bicuculline administration, which would indicate functionally elevated levels of calcium at this time point that could also activate eEF2K. To test this hypothesis directly, APV and nifedipine were administered for the last 10 min of 60 min of bicuculline administration (Fig. 3A), resulting in a reversal of the synaptic activity-induced increase in eEF2 phosphorylation.
bicuculline-induced increase in ERK phosphorylation (Fig. 3B). Furthermore, chelating extracellular calcium via EGTA administration during the last 10 min of a 60 min application of bicuculline also reversed the increase in ERK phosphorylation (Fig. 3C). These data suggest that functionally elevated levels of calcium are present after 60 min of bicuculline administration and that the decrease in eEF2 phosphorylation at this time point is most likely attributable to an active inhibition of eEF2K activity by other signaling pathways and not a decrease in intracellular Ca\textsuperscript{2+}.

Both the mTORC1 and MEK/ERK pathways are known to be negative regulators of eEF2K activity (Wang et al., 2001; Carroll et al., 2004; Inamura et al., 2005), and both pathways are stimulated in response to bicuculline administration in cortical neurons (Fig. 1). To determine whether these signaling pathways are involved in returning eEF2K activity to baseline levels during prolonged bicuculline administration, either an MEK inhibitor (AZD6244) or an mTORC1 inhibitor (rapamycin) was administered before 20 or 60 min of bicuculline administration. Inhibition of either mTORC1 or MEK/ERK prevented the decrease in eEF2 phosphorylation after 60 min of bicuculline-stimulated synaptic activity (Fig. 3D). Furthermore, administration of AZD6244 alone resulted in a trend toward an increase in eEF2 phosphorylation, whereas rapamycin alone was without effect. This suggests that, at both basal and elevated levels of synaptic activity, the MEK/ERK pathway maintains tight regulation of eEF2K, whereas the mTORC1 pathway is only important during prolonged synaptic activity in cortical neurons. We also examined the regulation of S6 and ERK phosphorylation in this experiment and found that, although rapamycin had no effect on ERK phosphorylation (Fig. 3E), AZD6244 administration resulted in a modest inhibition of S6 phosphorylation (Fig. 3F). This suggests that the mTORC1 pathway is downstream of the MEK/ERK pathway in cortical neurons, as has been reported previously in some cell types, such as hippocampal neurons, but not others (Kelleher et al., 2004; Roux et al., 2004; Ma et al., 2005; Fonseca et al., 2011).

**Development of a kinetic model for the regulation of eEF2K**

To test the hypothesis that Ca\textsuperscript{2+}/CaM-dependent Ras GRP (Caloca et al., 2003); (2) a module for mTORC1/S6K1 phosphorylation based on the mechanism described by Lenz and Avruch

**Figure 2.** Elevated synaptic activity increased eEF2 phosphorylation via ionotropic receptors. A, B, The effects of pretreating neurons with receptor inhibitors before bicuculline (Bic) stimulation for 10 (A) or 1 (B) min on p-eEF2 and p-ERK with representative Western blots below the graphs. One-way ANOVAs revealed effects of treatment at both 10 min (p-eEF2, \( F_{(2,14)} = 3.5, p < 0.001; \) p-ERK, \( F_{(2,14)} = 7.4, p < 0.001; \) n = 4–7) and 1 min (p-eEF2, \( F_{(2,14)} = 9.6, p < 0.001; \) p-ERK, \( F_{(2,14)} = 8.7, p < 0.001; \) n = 4–8). C, The effect of administering EGTA immediately before bicuculline stimulation on p-eEF2 and p-ERK with representative Western blots shown below. A 3 × 2 (bicuculline × EGTA) ANOVA revealed a main effect of EGTA (p-eEF2, \( F_{(1,14)} = 42.9, p < 0.001; \) p-ERK, \( F_{(1,14)} = 50.4, p < 0.001 \) ) and an interaction between 1 min of bicuculline administration and EGTA (p-eEF2, \( F_{(1,14)} = 12.6, p = 0.003; \) p-ERK, \( F_{(1,14)} = 14.0, p = 0.002; \) and 10 min of bicuculline administration and EGTA (p-eEF2, \( F_{(1,14)} = 5.2, p = 0.039; \) p-ERK, \( F_{(1,14)} = 41.7, p < 0.001; \) n = 2–4). Data represent mean ± SEM; \( * p < 0.05 \) compared with untreated neurons (NT), \( \beta p < 0.05 \).
Figure 3. Both the MEK/ERK and mTORC1 pathways are involved in returning eEF2 phosphorylation back to baseline levels during continuous bicuculline (Bic) administration. A, Schematic depicting the experimental design for B and C. APV/nifedipine (Nif) or EGTA was administered during the last 10 min of a total period of 60 min of bicuculline administration. B, C, The effect of administering APV and nifedipine or EGTA during the last 10 min of continuous bicuculline administration on p-ERK. The 2 × 2 (bicuculline × APV/nifedipine or bicuculline × EGTA) ANOVAs revealed main effects of bicuculline (F(1,12) = 68.8, p < 0.001; F(1,12) = 15.2, p = 0.005, respectively), a main effect of APV/nifedipine (F(1,12) = 124.6, p < 0.001) or EGTA (F(1,12) = 21.8, p = 0.002), and an interaction between bicuculline and APV/nifedipine or EGTA (F(1,12) = 59.5, p < 0.001) or bicuculline and EGTA (F(1,12) = 19.7, p = 0.002); n = 3–4. D-F, The effects on p-eEF2, p-ERK, and p-S6 (240/244) of administering AZD6244 or rapamycin (Rap) before bicuculline administration for 0, 20, or 60 min. The 3 × 3 (time × inhibitor) ANOVAs revealed main effects of time on p-eEF2 (F(2,37) = 12.6, p < 0.001), p-ERK (F(2,37) = 14.5, p < 0.001), and p-S6 (F(2,37) = 11.9, p < 0.001), main effects of inhibitor on p-eEF2 (F(2,37) = 8.3, p < 0.001), p-ERK (F(2,37) = 85.9, p < 0.001), and p-S6 (F(2,37) = 67.6, p < 0.001), and no interaction between time and inhibitor on p-eEF2 (F(4,74) = 1, p = 0.46) but interactions on p-ERK (F(4,74) = 4.9, p = 0.003) and p-S6 (F(4,74) = 4.9, p = 0.003); n = 5–7. G, Representative Western blots for data presented in D-F. Data represent mean ± SEM; *p < 0.05, †p < 0.10 compared with untreated neurons (NT).
and AZD6244 or rapamycin and reduced the value for a least-squares fit cost function for p-ERK, p-S6, and p-eEF2 by 60% (Fig. 5C, D).

Involvement of AMPK in the regulation of eEF2K

Our computational model demonstrated that the combined activity of the MEK/ERK and mTORC1 pathways is sufficient to explain the short-term dynamics of eEF2K regulation in response to elevated synaptic activity (10–20 min after bicuculline administration (Fig. 5B). However, the longer-term dynamics (i.e., at 40–60 min) were not fully captured, because the model predicted significantly lower levels of eEF2 phosphorylation than was observed experimentally (Fig. 5B). Intuitively, this could be interpreted as though an additional positive regulator of eEF2K, with sustained activity up to 60 min, was lacking from the model. Thus, we considered two known positive regulators of eEF2K: (1) protein kinase A (PKA) and (2) AMPK (Redpath and Proud, 1993; Horman et al., 2003; Browne et al., 2004). Previous work has found that cAMP, a key upstream effector of PKA, does not increase in response to bicuculline, membrane depolarization, or glutamate application in neurons (Pokorska et al., 2003), whereas AMPK is known to be activated by CaMKKβ (Hawley et al., 2005; Woods et al., 2005). Therefore, we focused on AMPK as the missing positive regulator.

The model was extended to include a fourth module that describes AMPK activation in response to elevated intracellular Ca^{2+} that results in additional activation of eEF2K (Fig. 1, orange). In addition, we also incorporated the negative regulation of mTORC1 by AMPK (Inoki et al., 2003; Kimura et al., 2003). The now updated model was again fitted to the same set of experimental data as before, but this time only the AMPK and eEF2-related parameters were free to change while the rest of the parameters remained constrained. As expected, the addition of AMPK in the model substantially improved model performance. The four-pathway model resulted in an excellent fit of eEF2 phosphorylation after 40–60 min of bicuculline stimulation without loss of fitting ERK and S6 phosphorylation (Fig. 6A).

We tested experimentally whether bicuculline-induced synaptic activity results in increased AMPK activity via Ca^{2+} influx and whether it influences eEF2K activity. Bicuculline administration resulted in a rapid and sustained increase in the phosphorylation of both AMPK (T172) and ACC, a well-defined AMPK substrate (Fig. 6B–D). Furthermore, the observed activation profile of AMPK was qualitatively very similar to that predicted by the mathematical model (Fig. 6E). To determine whether AMPK activation alone is sufficient to stimulate eEF2K, we used A769662, a selective activator of AMPK (Cool et al., 2006; Guigas et al., 2009). A769662 resulted in an increase in both ACC and

---

*Figure 4.* Depiction of various pathways that are known to contribute to eEF2K regulation in systems biology graphical notation (SBGN) activity flow format (Le Novere et al., 2009). Arrows represent activation, plungers represent inhibition, and diamonds represent modulation when both activation and inhibition are possible depending on other inputs. Filled boxes indicate components of the computational model with colors associated with specific pathways: red for MEK/ERK, brown for mTORC1, light green for Ca^{2+}/CaM input, dark green for eEF2K output, and orange for AMPK. Colored framed boxes for TSC1/2 (mTORC1 pathway) and p90RSK (MEK/ERK pathway) correspond to components that are implied in the model although not represented by specific parameters. Black framed boxes correspond to pathway elements not explicitly considered in the model. LKB1, Liver kinase B1; P3K, phosphatidylinositol 3-kinase; RTK, receptor tyrosine kinase; TSC1/2, tuberous sclerosis complex 1/2.
eEF2 phosphorylation (Fig. 6F, G). A769662 did not alter AMPK phosphorylation, consistent with A769662 being an allosteric modulator of AMPK (Göransson et al., 2007; Sanders et al., 2007), but did result in a decrease in S6 phosphorylation, consistent with AMPK negatively regulating mTORC1 (Inoki et al., 2003; Kimura et al., 2003). However, it is unlikely that the effect of A769662 on mTORC1 is responsible for the increase in eEF2 phosphorylation given that rapamycin administration alone, which results in a greater decrease in S6 phosphorylation than A769662, did not affect eEF2 phosphorylation (Fig. 4B). Finally, APV and nifedipine were applied during the last 10 min of a 60 min period of bicuculline stimulation (Fig. 3A). This reversed the synaptic activity-induced increase in both AMPK and ACC phosphorylation (Fig. 6H–J), indicating that AMPK is regulated by Ca\(^{2+}\) influx through NMDARs and L-VGCCs in response to elevated synaptic activity in neurons.

Comparison of models with and without AMPK
To further validate the inclusion of AMPK into the model, we sought a means to directly compare predictions from models with and without AMPK. In particular, we were interested in predictions based on conditions in which experimental data had not been obtained previously and used for model fitting. We noted that our initial model without AMPK predicted a higher level of eEF2 phosphorylation after 1 min of bicuculline administration in the presence of either rapamycin or AZD6244 compared with bicuculline alone (Fig. 5, compare B with C,D). We then generated a prediction under the same conditions using the model that includes AMPK. The inclusion of AMPK resulted in a substantially lower prediction for the levels of bicuculline-induced eEF2 phosphorylation in the presence of either rapamycin or AZD6244 (Fig. 7A). We tested these two contrasting predictions experimentally and found that 1 min of bicuculline administration in the presence of either rapamycin or AZD6244 results in only a very modest increase in eEF2 phosphorylation over bicuculline alone (Fig. 7B). Furthermore, a comparison of the predictions of the two models (with and without AMPK) with the experimental data indicated that the model that includes AMPK results in a much closer match to the empirical findings (Fig. 7C).

To determine why the model that included AMPK resulted in a lower relative increase of p-eEF2 after bicuculline administration in the presence of AZD6244 or rapamycin than the model that did not include AMPK, we more closely examined the values for p-eEF2 during the steady state and in response to bicuculline in the two models. We found that the discrepancy between the two models was primarily attributable to differences in baseline levels of p-eEF2. The model that included AMPK had higher basal concentrations of p-eEF2 than the model without AMPK (4.0 vs 0.7 nM). After 1 min of bicuculline administration in the
Figure 6: Modeling and experimental evidence implicate AMPK regulation of eEF2K in cortical neurons. 

A. Simulation of bicuculline administration in cortical neurons (solid lines) compared with experimental data (dashed lines) with the inclusion of AMPK in the kinetic model.

B. The effect of continuous bicuculline administration on p-AMPK (T172) and p-ACC. One-way ANOVAs revealed effects of stimulation on p-AMPK (F(7,61) = 4.7, p < 0.001) and p-ACC (F(7,62) = 4.7, p < 0.001); n = 8–9.

C. Comparison of model prediction of p-AMPK (solid line) with experimental data (dashed line). The effects of administering APV and nifedipine (Nif) during the last 10 min of a 60 min bicuculline (Bic) stimulation (Fig. 3A) on p-AMPK and p-ACC. The 2 × 2 ANOVAs revealed a main effect of bicuculline treatment on both p-AMPK (F(1,12) = 10.6, p = 0.007) and p-ACC (F(1,12) = 6.9, p = 0.02), a main effect of APV and nifedipine on p-AMPK (F(1,12) = 19.1, p = 0.001), a trend toward an effect on p-ACC (F(1,12) = 3.7, p = 0.077), a trend toward an interaction on p-AMPK (F(1,12) = 3.2, p = 0.099), and no interaction for p-ACC (F(1,12) = 1.4, p = 0.27); n = 4.

D. Representative Western blots for data presented in B and C. The effects of administering 100 μM A769662 for 60 min to cortical neurons on p-eEF2, p-AMPK, p-ACC, p-S6 (S240/244), and p-ERK. A769662 resulted in an increase in p-eEF2 (t(10) = 3.0, p = 0.012) and p-ACC (t(10) = 3.1, p = 0.011) and a decrease in p-S6 (t(10) = 6.8, p < 0.001) and had no effect on p-AMPK (t(10) = 1.1, p = 0.31) or p-ERK (t(10) = 1.1, p = 0.30); n = 6.

J. Representative Western blots for data presented in H and I. Data represent mean ± SEM; *p < 0.05, †p = 0.10 compared with untreated neurons (NT).
presence of, for example, rapamycin, the model with AMPK predicted an increase in p-eEF2 to a concentration of 20 nM, whereas without AMPK the model predicted 5.5 nM. Thus, as would be expected, the model including AMPK resulted in higher absolute concentrations of p-eEF2 but lower relative increases after bicuculline stimulation in the presence of AZD6244 or rapamycin (Fig. 7C).

**Sensitivity analysis**

We performed sensitivity analysis of our final model to determine which pathways made the greatest contribution to the regulation of p-eEF2 (see Notes). We found that, although both the MEK/ERK and mTORC1 pathways significantly contribute to the levels of p-eEF2, the parameters with the largest influence arise from the AMPK pathway. This is consistent with our experimental data in which we find that inhibiting the MEK/ERK or mTORC1 pathways in the absence of bicuculline has modest effects on p-eEF2 (Fig. 3D), whereas activating AMPK alone is sufficient to increase p-eEF2 (Fig. 6F).

**Discussion**

We find that synaptic activity-induced eEF2K regulation in primary neurons is both rapid and dynamic. The regulation of eEF2K depends on Ca^{2+} influx through ion channels/receptors and the Ca^{2+} coordinated regulation of various cell signaling pathways. We used a data-driven mechanistic model to test the hypothesis that Ca^{2+}-coordinated mTORC1 and MEK/ERK regulation could explain the observed eEF2K dynamics. Initial discrepancies and additional iterations between modeling and experimental work found that AMPK is also a key determinant of synaptic activity-induced eEF2K signaling in neurons.

The use of primary neuronal cell cultures to examine the intricacies of cell signaling in the present study has both strengths and weaknesses. Whereas the vast majority of biochemical studies of eEF2K, mTORC1, MEK/ERK, and AMPK are performed in cancer cell lines with stimuli that may have only tangential relevance to neuronal signaling, primary neuronal cultures provide direct access to an untransformed, mostly homogenous population of neurons and the use of neuronally relevant stimuli. However, given that the brain is actually a heterogeneous mixture of many cell types and contains well defined circuitry that is unlike the stochastic connectivity of neurons in culture, care must be taken when interpreting results from neuronal cultures in the context of whole-brain function. Nonetheless, the findings from the present study may shed light on some of the complex findings regarding the regulation of eEF2K in the brain and neurons. For example, after the acquisition of a conditioned taste aversion learning task in mice, there is an increase in eEF2 phosphorylation in the gustatory cortex (Belelovsky et al., 2005; Gildish et al., 2012). In contrast, after the acquisition of contextual fear conditioning, there is a decrease in eEF2 phosphorylation in the hippocampus (Im et al., 2009). In addition, differential compartmental regulation of eEF2K has been found in *Aplysia* sensory neurons in...
which 5-HT application results in a decrease in eEF2 phosphorylation in neurites but an increase at the soma (Carroll et al., 2004; Weatherill et al., 2011), and the application of BDNF to primary neurons results in a decrease in eEF2 phosphorylation (Takei et al., 2009) but BDNF applied to the dentate gyrus in vivo results in increased eEF2 phosphorylation (Kanoh et al., 2006). Finally, eEF2K activity at the synapse has been found to decrease after evoked synaptic transmissions but to increase as a result of spontaneous transmission (Sutton et al., 2007). Our finding that considering only mTORC1 and MEK/ERK signaling was insufficient to describe eEF2K dynamics suggests a possible explanation for many of these disparate findings. Indeed, most studies examining the regulation of eEF2K in neuronal preparations have focused on the role of the mTORC1 signaling pathway (Carroll et al., 2004; Inamura et al., 2005; Weatherill et al., 2011) with scant attention paid to the MEK/ERK pathway (Belelovsky et al., 2005; Kanoh et al., 2006) and none to AMPK. Although our findings make use of whole-cell lysates, in which ~95% is thought to be nonsynaptic in origin (Chang et al., 2012), our data suggest that an examination of all three of these pathways in the various preparations is required to adequately assess eEF2K dynamics. Doing so will likely help explain the apparent differences in eEF2K regulation across different compartments, brain regions, and neuronal preparations.

The rapid regulation of eEF2K by elevated synaptic activity that we have examined and modeled provides a framework for a deeper understanding of some of the mechanisms involved in a variety of synaptic activity-related phenomena, such as learning and memory, synaptic plasticity, and neuroprotection. The rapid bicuculline-induced increase in eEF2K activity in cortical neurons in the present study was found to depend on NMDA and AMPA-type GluRs, mechanisms known to be necessary for both memory acquisition and the induction of long-term potentiation (Abel and Lattal, 2001). Furthermore, the involvement of the MEK/ERK and mTORC1 pathways in learning and synaptic plasticity are well documented (Kelleher et al., 2004; Sweatt, 2004; Costa-Mattioli et al., 2009), and, more recently, the AMPK pathway has been implicated in both synaptic plasticity (Potter et al., 2010) and learning (Dagon et al., 2005; Dash et al., 2006). This suggests that that eEF2K may be an important downstream effector of these pathways in the context of learning. The administration of bicuculline to primary neurons for considerably longer periods than examined here also results in a modest mGlur-dependent increase in eEF2 phosphorylation (Verpell et al., 2010), a mechanism important for the induction of long-term depression (Park et al., 2008). This longer-term bicuculline administration more closely models homeostatic plasticity (Desai, 2003), thereby suggesting that eEF2K may be involved in multiple forms of plasticity. Finally, bicuculline-induced synaptic activity is also known to be neuroprotective (Hardingham et al., 2002; Lee et al., 2005). AMPK presents an intriguing target for understanding bicuculline-induced neuroprotection given that it is not only stimulated by Ca2+ but is also a key sensor of energy/ATP in the cell that makes significant contributions to phenomena such as ischemia (Ronnett et al., 2009). Given that eEF2K regulates one of the most energy-consuming processes in cells and is important for cell survival in non-neuronal cells (Terai et al., 2005; Lepriver et al., 2013), there may be interesting and complex relationships between Ca2+ influx, ATP, AMPK, and eEF2K in regulating neuroprotection that requires additional study.

The cell signaling network in neurons is large, complex, and incompletely understood. Although formal mathematical models are a powerful approach for testing specific hypotheses about whether a given set of molecular interactions is sufficient to explain empirical findings, such models require a delicate balance between including too many and too few parameters (Di Ventura et al., 2006). In addition, there is little information regarding the specific concentrations of proteins and dissociation constants for model development, making it imperative to minimize the parameter space explored while simultaneously ensuring that the appropriate network of interactions is maintained. Inclusion of more parameters than necessary to describe a particular network structure can lead to overfitting and a loss of biological plausibility. In the present study, we circumvented some of these issues by focusing on pathways in which we had high-quality data and carefully designed our model to test a specific hypothesis, i.e., can we explain eEF2K dynamics given the activation profiles of the mTORC1 and MEK/ERK pathways? By initially fitting the mTORC1 and MEK/ERK modules of the model to the p-S6 and p-ERK data and only then attempting to fit the eEF2K module to the p-eEF2 data (Fig. 5A), we directly tested this hypothesis. Although the initial model only incompletely fit the eEF2 phosphorylation data, it did yield a strikingly accurate prediction of AMPK activation in response to bicuculline (Fig. 6E). This approach also resulted in realistic estimates of [Ca2+]. Fitting Ca2+-related parameters to the experimental data resulted in a value for resting-state [Ca2+] of 59 nM and a bicuculline-induced peak of 54 μM, both of which are in line with empirical observations (Petrozzino et al., 1995; Maravall et al., 2000). Furthermore, the model including AMPK accurately predicted eEF2 phosphorylation levels under conditions in which the model was never fit to experimental data (Fig. 7). Together, these findings support the contention that our model accurately captures the major features of the signaling dynamics involved in eEF2K regulation.

Our ODE model clearly captures a high proportion of eEF2K regulatory dynamics with demonstrated predictive validity, making it useful for additional hypothesis generation and experimental testing. For example, whereas the inhibitory inputs into eEF2K from the MEK/ERK and mTORC1 pathways were modeled as phosphorylation events that inactivate eEF2K, the details of this mechanism require additional exploration. We tested, in silico, the two most obvious and simple mechanisms of inactivation and found that phosphorylation-induced inhibition of active Ca2+/CaM-bound eEF2K fits the experimental data better than a mechanism in which phosphorylation of eEF2K prevents its binding to Ca2+/CaM. Nonetheless, there are additional elements that should be considered for the future development of a more complex model. For example, eEF2K has been reported recently to be controlled by cyclin-dependent kinase-2 (Hair et al., 2013) and undergoes significant regulatory autophosphorylation (Pyr Dit Ruys et al., 2012; Tavares et al., 2012). Additional iterations between modeling and experiments would determine what role these events and others may play in eEF2K dynamics, leading to a more sophisticated and nuanced understanding of the mechanisms underlying eEF2K regulation in various conditions.

Taken together, the experimental data and modeling in the present study provide the first in-depth examination of the dynamics of eEF2K regulation. Although previous work studying eEF2K in neurons focused primarily on its regulation by
mTORC1 with some consideration of MEK/ERK, our combined data and modeling suggest that such an approach is inadequate for understanding eEF2K regulatory dynamics: AMPK also makes a substantial contribution of eEF2K regulation in both the short and intermediate terms. Continuing refinement of the model and better understanding of the control of eEF2K will provide insights into diverse eEF2K-regulated processes, such as learning and memory, ischemia, and cell survival (Gal-Ben-Ari et al., 2012; Romero-Ruiz et al., 2012; Leprivier et al., 2013).

Notes
Supplemental material for this article is available at http://www.inf.ed.ac.uk/~jda/eEF2k. It includes the following: (1) a supplemental file describing the model in greater detail, including all equations in the model, a detailed process diagram of model, and details of the sensitivity analysis and figures; (2) a table of the model parameters; and (3) the model in SBML format. This material has not been peer reviewed.

References
Inamura N, Nawa H, Takei N (2005) Enhancement of translation elongation in neurons by brain-derived neurotrophic factor: implications for


